Author
Unnikrishnan is currently Senior Associate Editor with BW Businessworld at its Mumbai Bureau. During his two decades long journalistic career, he has received several media awards and recognitions. His articles on healthcare, life sciences and intellectual property rights (IPR) have been republished by several international blogs and journals.
For Diageo, the legal ground for initiating a case against Mallya in the UK is very strong. After all, fund diversion at the Indian subsidiary ultimately harms the parent company that is based in the UK
Read More
Gupta is praised for making many contributions to public policy, innovation and healthcare over the past decade
Read More
Vijay Mallya’s warring partner and UK distiller Diageo could very well drag the fund diversion case that it investigated in its Indian subsidiary to a UK court soon, if legal experts are to be believed
Read More
Drug firm Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the production of biosimilars
Read More
ItzCash claims that it has crossed Rs 50,000 crore worth of cumulative gross payment volume for all bill payments till date
Read More
Sanofi and Boehringer Ingelheim have active presence in India and the business impact of their deal will be significant once it is successfully closed
Read More
The $465 million (Rs 3,018 crore) initial public offering (IPO) by InterGlobe Aviation, the parent of India’s largest airline Indigo, in October 2015 created many a record.
Read More
The joint venture has been established to co-produce Boeing AH-64 Apache helicopter fuselages and other aero-structures
Read More
FundTonic, with its current focus on India as its targeted market, plans to deepen the start-up eco-system in Tier 1 cities and build infrastructure in Tier 2 and Tier 3 cities by making partnerships to achieve the larger objective of identifying and scaling disruptive ideas across the country
Read More
The portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business, the Hyderabad-based firm said
Read More
